Saudi Biotherapeutics Company
RESEARCH & INNOVATION
Research and innovation are at the core of Madarik’s mission. We focus on autologous biological therapies for chronic wounds, beginning with the RAPID Biodynamic Haematogel platform for diabetic foot ulcers, and on the intelligent use of data and AI to support better clinical decisions.
Evidence Base
Collaborations
Madarik works with international technology partners, local key opinion leaders, and leading hospitals to design and implement studies that reflect real‑world practice in the Kingdom. We are committed to generating transparent, publishable data that can guide clinicians, payers, and policymakers as they redesign diabetic foot care pathways.ls could fit on a pin head and a drop of blood contains around 250,000 platelets.
Our current solution is underpinned by a substantial body of clinical evidence, including randomized controlled trials and real‑world studies in chronic diabetic foot ulcers and other complex wounds. These data have contributed to FDA device clearance, reimbursement decisions, and SFDA approval, and they provide a strong foundation for adapting the therapy to the Saudi population.
Key Research Themes
We are developing and supporting research in three priority areas:
-
Optimising treatment protocols for high‑risk diabetic foot ulcer patients with multiple comorbidities.
-
Integrating AI‑driven image analysis into routine wound assessment and follow‑up.
-
Assessing the impact of biotherapeutic treatment on amputation rates, hospital utilisation, and total cost of care in Saudi Arabia.